UPLC-MS/MS测定大鼠尿样中26-OH-PD浓度的不确定度评定

目的 评定超高液相色谱-串联质谱法（UPLC-MS/MS）测定大鼠尿样中26-OH-PD浓度的不确定度。方法 分析UPLC-MS/MS法测定大鼠尿样中26-OH-PD浓度的不确定度来源,根据各分量计算出合成不确定度并进行了扩展。结果 大鼠尿样中低浓度（6.16 ng/mL）、中浓度（97.94 ng/mL）和高浓度（398.02ng/mL）26-OH-PD的扩展不确定度分别为1.44、6.97、22.05 ng/mL（P=95%,k=2）。结论 UPLC-MS/MS法测定大鼠尿样中26-OH-PD低浓度样品的不确定度主要分别由线性拟合引入,中、高浓度样品的不确定度主要由仪器允差引入。该法适用于评定UPLC-MS/MS法测定尿样中26-OH-PD的不确定度研究,能为复杂生物样品分析过程的不确定度评定提供一定参考。     

超高效液相色谱-串联质谱法测定大鼠血浆及组织中贝达喹啉浓度及其药动学考察

目的:建立超高效液相色谱-串联质谱(UPLC-MS/MS)法测定SD大鼠血液及组织中贝达喹啉的浓度,研究其在大鼠体内的药动学及组织分布.方法:采用UPLC-MS/MS联用技术,测定大鼠血液及组织中贝达喹啉的药物浓度,并利用DAS软件及非房室模型统计矩方法计算药动学参数.结果:贝达喹啉线性范围为0.1～500 ng·mL...     

UPLC-MS/MS测定大鼠血浆中26-OH-人参二醇浓度的不确定度评定

目的评定超高效液相色谱-串联质谱(UPLC-MS/MS)法测定大鼠血浆中26-OH-人参二醇浓度的不确定度。方法分析UPLC-MS/MS法测定大鼠血浆中26-OH-人参二醇浓度的不确定度来源,根据各分量计算出合成不确定度并进行了扩展。结果大鼠血浆中低(13.87 ng·mL~(-1))、中(188.04ng·mL~(-1))和高(824.33 ng·mL~(-1))浓度26-OH-人参二醇的扩展不确定度分别为3.63、12.41和66.61ng·mL~(-1)(P=95%,k=2)。结论 UPLC-MS/MS法测定大鼠血浆中26-OH-人参二醇低浓度样品的不确定度主要分别由线性拟合引入,中、高浓度样品的不确定度主要由基质效应引入。该法适用于评定UPLC-MS/MS法测定血浆中26-OH-人参二醇的不确定度研究,能为复杂生物样品分析过程的不确定度评定提供一定参考。     

高效液相色谱-质谱法检测血清中维生素D含量

目的建立测定血清中25-羟基D2和25-羟基D3含量的高效液相色谱-质谱法。方法采用固相萃取柱对血清样品进行处理和净化,以0.1%甲酸水溶液-0.1%甲酸的甲醇溶液(15∶85)为流动相,检测波长为240 nm,柱温为50℃,流速为0.5 mL/min为色谱条件,以ESI+APCI组合离子源,正离子模式;离子源喷射电压5 000 V,离子源温度250℃,离子源喷雾流速5 L/min为质谱条件。结果建立的分析方法 25-羟基D2和25-羟基D3质量浓度线性范围在5~100 ng/mL范围与峰面积有良好线性关系(R2=0.999 2,0.999 5),日内精密度均低于5%,日间精密度均低于10%,回收率在96.19%~108.23%之间,血清中检测限和定量限分别是2 ng/mL和3 ng/mL。结论所建立的方法准确、灵敏、可重复,可用于检测血清中25-羟基D2和25-羟基D3的含量。     

UPLC-MS/MS法测定苯磺酸氯吡格雷中5种遗传毒性杂质

利用超高效液相色谱-三重四级杆质谱联用仪（ultra performance liquid chromatography-tandem mass spectrometry, UPLC-MS/MS）建立了一种测定苯磺酸氯吡格雷中5种苯磺酸酯类遗传毒性杂质的方法,并进行了方法学验证。结果表明,方法的定量限和检出限均较低,其中,对硝基苯磺酰氯、对硝基苯磺酸的检出限和定量限分别为0.045 ng/mL和0.150 ng/mL,对硝基苯磺酸甲酯、对硝基苯磺酸乙酯、对硝基苯磺酸异丙酯的检出限和定量限分别为0.113ng/mL和0.375 ng/mL。5种遗传毒性杂质在其线性范围内线性关系良好,相关系数在0.9987～0.9998之间,重复性RSD值在0.69%～1.85%之间,加标回收率在82.98%～119.92%之间,方法的线性、精密度、准确度、耐用性等均满足定量分析要求。因此,该方法适用于苯磺酸氯吡格雷中5种遗传毒性杂质的检测。     

UPLC-MS/MS法同时检测人血清中5种微量内源性激素

目的：建立一种快速、高效的同时检测人血清中睾酮（T）、雄烯二酮（AD）、脱氢表雄酮（DHEA）、孕酮（P）和17α-羟孕酮（17α-OHP）浓度的UPLC-MS/MS方法。方法：血清样品采用盐酸羟胺衍生化提高离子化效率,以同位素氘标记的P-d9作为内标,采用Agilent ZORBAX Eclipse Plus Phenyl-Hexyl色谱柱(2.1×100mm,3.5μm),0.1%甲酸水（A）-乙腈（B）为流动相,以0.3mL/min流速梯度洗脱分离后,在电喷雾离子源正离子模式下扫描,分析时间5min。结果：在0.05~100ng/mL浓度范围内,5种激素呈现良好线性关系,定量下限均达到0.05ng/mL,批内、批间精密度和准确度均符合要求,平均提取回收率和归一化基质因子变异均在15%以内。该方法成功用于实际血清样本中5种激素的定量分析。结论：该方法快速、灵敏度高、稳定性好、专属性强,满足临床血清样本中5种内源性雄激素和孕激素的分析要求。     

UPLC-MS/MS法检测人体毛发中右美沙芬及其代谢物去甲右美沙芬

目的:建立一种准确、快速检测毛发中右美沙芬及其代谢物去甲右美沙芬的超高效液相色谱-串联质谱(UPLC-MS/MS)方法。方法:用含内标双苯戊二氨酯(SKF_525A)的甲醇溶液提取含有右美沙芬及其代谢物的毛发,经0.22μm微孔有机滤膜过滤,UPLC-MS/MS检测。采用ACQUITY UPLC HSS T3超高液相色谱柱(100 mm×2.1 mm, 1.8μm),以0.2%甲酸(10 mmol·L^-1甲酸铵)和乙腈为流动相进行梯度洗脱,流速0.3 mL·min^-1,柱温为室温。采用电喷雾离子源,正离子多反应模式检测。结果:右美沙芬和去甲右美沙芬质量浓度均在1～100 ng·mL^-1范围内线性响应良好,线性方程分别为Y=1.349 49X-0.020 80 (r=0.998 8)和Y=0.775 10X-0.013 87 (r=0.999 1),检测限和定量限均分别为0.01 ng·mL^-1和0.025 ng·mL^-1,平均回收率在97.0%～104.8%...     

胡桃醌对大鼠血清中与脑组织损伤相关生物标志物的影响

目的:考察胡桃醌对大鼠脑组织的影响及其与脑组织损伤相关生物标志物的关系。方法:将40只大鼠分为空白组和胡桃醌高、中、低剂量组(34.832、17.416、8.708 mg/kg),每组10只,每天灌胃给药1次,连续给药4周。末次给药后,考察各组大鼠的一般行为学、脑指数及脑组织病理形态。采用超高效液相色谱-多反应检测质谱(UPLC-MRM-MS)法检测各组大鼠血清中左旋多巴(L-Dopa)、L-酪氨酸(L-Tyr)、L-色氨酸(L-Trp)的含量。色谱条件为色谱柱Waters Acquity UPLC BEH C18,流动相为乙酸铵水溶液-乙腈,梯度洗脱,流速为0.3 mL/min,进样量为5μL,柱温为30℃;质谱条件为电喷雾离子源,正离子模式下检测,毛细管电压为3 500 V,去溶剂气流量为650 L/h,去溶剂化温度为350℃,离子源温度为110℃。结果:与空白组比较,胡桃醌各剂量组大鼠出现倦怠、四肢无力的行为;脑组织可见大、小脑皮质内血管充血,锥体细胞层部分神经元固缩,核深染,形态不规则,边界不清晰等病理性改变;胡桃醌高剂量组脑指数显著增加(P<0.05)。建立的UPLC-MRM-MS法专属性良好,L-Dopa、L-Tyr、L-Trp的检测质量浓度线性范围分别为31.25～32 000、31.25～32 000、15.625～16 000 ng/mL(r=0.999 1～0.999 9),检测限分别为6.250、5.625、3.125 ng/mL,定量限分别为15.625、18.75、10.00 ng/mL,精密度、准确度、稳定性(24 h)试验RSD均小于2.6%(n=6),基质效应为95.1%～100.1%(RSD均未超过3.25%,n=3)。动物实验结果显示,与空白组比较,胡桃醌中、高剂量组L-Dopa含量显著升高(P<0.01);胡桃醌低、中、高剂量组L-Tyr含量显著升高,L-Trp含量显著降低(P<0.05或P<0.01)。结论:胡桃醌对大鼠的行为学、脑指数、脑组织形态均有明显影响,可能通过升高血清中L-Dopa、L-Tyr的含量,降低L-Trp的含量影响大鼠的脑组织功能。     

龙胆健肝胶囊在大鼠体内的药物代谢动力学研究

目的 研究龙胆健肝胶囊在大鼠体内的药物代谢动力学。方法 采用超高效液相色谱串联质谱(UPLC-MS/MS)法测定大鼠血浆中龙胆健肝胶囊8个成分的含量。色谱条件,色谱柱为Polaris C₁₈-A柱(100 mm×2.1 mm,1.8μm),流动相为甲醇-0.1%甲酸水溶液(梯度洗脱),流速为0.3 mL/min,柱温为30℃,进样量为10μL;质谱条件,电喷雾离子源(ESI),多反应监测(MRM)模式,毛细管电压3 000 V,鞘气(GS1)压力35 Arb,辅助气(GS2)压力7 Arb,毛细管温度300℃,挥发气温度300℃。取SD大鼠6只,分别灌胃龙胆健肝胶囊0.80 g/kg,测定血药浓度,并用DAS 2.0软件计算药物代谢动力学参数。结果 龙胆苦苷、绿原酸、虎杖苷、金丝桃苷、橙皮苷、大黄酸、大黄素甲醚、川陈皮素质量浓度分别在31.52～2 017.03 ng/mL、4.03～257.96 ng/mL、3.29～216.75 ng/mL、18.51～1 184.64 ng/mL、9.03～577.92 ng/mL、14.24～911.36 ng/mL、30...     

UPLC-MS/MS法测定大鼠血浆中的豆腐果苷

目的 建立超高效液相色谱-串联质谱法(UPLC-MS/MS)测定大鼠血浆中的豆腐果苷.方法 蛋白沉淀法分离血浆样品;采用BEH C18色谱柱,0.1％甲酸-乙腈-水为流动相,梯度洗脱,离子化方式为负离子电喷雾,多反应监测,药物的监测离子对为m/z329→121.结果 豆腐果苷浓度在2～1000 ng/mL范围内线性关系良好,日内及日间精密度均小于15％,基质效应小于15％.结论本研究建立的方法 可应用于豆腐果苷药动学和生物利用度研究.     

超高效液相色谱-串联质谱法测定大鼠血浆中替诺福韦的浓度

目的:建立大鼠血浆中替诺福韦浓度的测定方法。方法:采用超高效液相色谱-串联质谱法。取6只大鼠单次灌胃给予富马酸替诺福韦酯100mg.kg-1,检测给药45min后血浆中药物浓度,以恩替卡韦为内标,选用阳离子固相萃取柱除去血浆中的蛋白质。色谱柱为AcquitybenUPLC-C18,流动相为0.2%甲酸水溶液(含40mmo.lL-1醋酸铵)-乙腈=97:3,流速为0.25mL.min-1,柱温为40℃,电喷雾正离子(ESI+)源,监测离子对分别为质荷比(m/z)287.9→175.7(替诺福韦)和m/z277.9→151.7(恩替卡韦)。结果:替诺福韦检测浓度的线性范围为10～800ng.mL-1(r=0.9992),最低检测限为10ng.mL-1,回收率为(100.22±9.47)%～(102.76±4.99)%,日间、日内RSD均小于9.4%;给药45min后血浆样品中替诺福韦的平均浓度为819.2ng.mL-1。结论:该方法操作简便、专属性强、灵敏度高,可用于血浆中替诺福韦的浓度测定。     

UPLC-MS/MS法测定血浆中新型酪氨酸酶抑制剂UP302的含量

目的:建立超高效液相色谱-串联质谱测定血浆中新型酪氨酸酶抑制剂UP302的方法,并用于研究UP302在大鼠、狗、猴和人血浆中的稳定性。方法:血浆中加入内标大豆苷元经2倍体积甲醇沉淀后进行分析。采用Hypersil Gold C18(50 mm×2.1 mm,1.9μm)色谱柱,流动相为甲醇(A)-5 mmol.L-1甲酸铵水溶液(B),梯度洗脱,梯度流速恒定为0.2 mL.min-1,柱温为30℃,整个分析时间为6 min。采用负离子电喷雾离子化电离源和选择反应监测模式进行检测。结果:在5～2000 ng.mL-1的浓度范围内,标准曲线线性关系良好(r=0.9998);血浆中UP302最低定量下限为5 ng.mL-1;本方法日内日间准确度在99.2%～107.3%,日内日间精密度均小于9.3%。结论:本方法灵敏度高,重现性好,操作简便,可用于血浆中UP302浓度的测定。     

Simple validated method of LC–MS/MS determination of BZ agent in rat plasma samples

Agent BZ (3‐quinuclidinyl benzilate) is a centrally acting synthetic anticholinergic agent, considered as a potential military incapacitating chemical warfare agent. Despite its significance as a model compound in pharmacological research and its potential misuse in chemical attacks, few modern analytical methods for BZ determination in biological samples have been published. The goal of the present work is to develop and validate a sensitive and rapid LC–MS/MS method for the determination of agent BZ in rat plasma. The sample preparation was based on solid‐phase extraction on C‐18 cartridges. The reversed‐phase HPLC coupled with the mass spectrometer with electrospray ionization in the positive ion‐selective reaction monitoring mode was employed in the BZ analysis. Atropine was used as an internal standard. The presented method is selective, accurate, precise, and linear (r² = 0.9947) in a concentration range from 0.5 ng/mL to 1 000 ng/mL and sensitive enough (limit of detection 0.2 ng/mL; limit of quantification 0.5 ng/mL) to determine the BZ plasma levels in rats exposed to 2 mg/kg and 10 mg/kg of BZ. The highest level of BZ in plasma was observed 5 minutes after intramuscular administration (154.6 ± 22.3 ng/mL in rats exposed to 2 mg/kg of BZ and 1024 ± 269 ng/mL in rats exposed to 10 mg/kg). After 48 h, no BZ was observed at detectable levels. This new method allows the detection and quantification of BZ in biological samples after exposure of an observed organism and it will be further optimized for other tissues to observe the distribution of BZ in organs.     

UPLC-MS/MS法检测复方芦丁片中芦丁的含量

目的建立超高效液相色谱-串联质谱法(UPLC-MS/MS)测定复方芦丁片中芦丁含量的方法。方法采用液相色谱串联质谱(LC-MS/MS)法。色谱柱为ACQUITY UPLC RBEH C 18色谱柱(2.1×100mm,1.7μm),流动相为甲醇-水溶液(42∶58),电喷雾离子化(ESI)正离子模式下选择质荷比(m/z)为301离子进行检测。结果所建方法能快速检测芦丁,在2.5~40.7ng·mL^-1浓度范围内线性关系良好(r=0.9995),平均加样回收率为99.5%,方法定量限为0.5ng·mL^-1,方法重复性和精密度良好。结论该方法专属性强,快速灵敏,适用于复方芦丁片中芦丁的含量测定。     

Determination and pharmacokinetics of danshensu in rat plasma after oral administration of danshen extract using liquid chromatography/tandem mass spectrometry.

A liquid chromatography/tandem mass spectrometry (LC/MS/MS) method was developed and validated for the determination and pharmacokinetics of danshensu in rat plasma samples using ferulic acid as internal standard (IS). The plasma samples were treated by liquid-liquid extraction, and the analyses were determined using electrospray negative ionization mass spectrometry in selected reaction monitoring (SRM) mode. The signal intensity of the m/z 196.8 --> 134.8 transition of danshensu was found to relate linearly to danshensu concentrations in the plasma from 5-500 ng/mL. The lower limit of quantification (LLOQ) as determined by the LC/MS/MS method amounted to 5 ng/mL. The intra- and inter-day precision was below 10.82%, and the accuracy was between -3.51% and +11.92%. The validated LC/MS/MS method was applied to a pharmacokinetic study in which danshen extract (containing 40 mg/g danshensu) was administered orally to rats at a single dose of 200 mg/kg in 2% water.     

Quantitative determination of doxorubicin in the exosomes of A549/MCF-7 cancer cells and human plasma using ultra performance liquid chromatography-tandem mass spectrometry

In cancer therapy, exosomes efflux enhances resistance of cancer cells toward anticancer agents through mediating the transport of anticancer drugs outside the cells. In this study, a rapid, simple and highly sensitive ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the determination of Doxorubicin (DOX) in exosomes of cancer cells and human plasma using Ketotifen as an internal standard (IS). Plasma samples spiked with DOX and two cancer cell lines (A549 & MCF-7) were incubated with different concentrations of DOX and IS. The analytes were then extracted with methanol after protein precipitation and the chromatographic separation was carried out using a C18 column, with a mixture of acetonitrile–water- formic acid (85:15:0.1%, v/v/v) as mobile phase. Multiple reaction monitoring (MRM) was utilized to monitor the protonated precursor to product ion transitions of m/z 544.25?>?397.16 and m/z 310.08?>?96.97 for the quantification of DOX and IS, respectively. The method was linear over ranges of 1–1000?ng/mL for DOX in plasma and 2–1000?ng/mL for DOX in exosome samples. The lower limit of quantification of this method was 1?ng/mL, 2?ng/mL and 2?ng/mL in human plasma, A549 & MCF-7 cells respectively. Intra- and inter day precision of all quality control concentrations were less than 10.33% and the accuracy values ranged from ?4.82 to 12.60%. The optimized UPLC-MS/MS method proved to be fast, specific, simple and highly sensitive and was successfully applied for the estimation of DOX in the exosomes of cancer cells and plasma.     

Determination of tropisetron in human plasma by liquid chromatography–tandem mass spectrometry

A sensitive and selective liquid chromatography–tandem mass spectrometry method (LC–MS/MS) for the determination of tropisetron in human plasma was developed and validated over the concentration range of 0.100–100 ng/mL. Diphenhydramine was used as the internal standard (IS). The tropisetron and the IS were extracted from alkalized plasma samples into diethyl ether–dichloromethane (2:1, v/v) and the LC separation was performed by a Diamonsil C₁₈ column (150 mm × 4.6 mm, i.d., 5 μm). The mobile phase was methanol:water (80:20, v/v) containing 0.2% formic acid delivered at a flow rate of 0.5 mL/min. The total chromatographic run time was 4.5 min. The MS data acquisition was accomplished by selected reaction monitoring (SRM) mode with positive atmospheric pressure chemical ionization (APCI) interface. The lower limit of quantification (LLOQ) achieved was 0.100 ng/mL with precision (RSD) of 3.1% and accuracy (RE) of −0.7%. For both inter-batch and intra-batch tests, the precision (RSD) for the entire validation was less than 6.0%, and the accuracy (RE) was within the −0.5% to 0.2% range. This validated LC–MS/MS method was later used to characterize the pharmacokinetics as well as the bioequivalence of tropisetron formulations.     

肺癌患者血浆中安罗替尼浓度与不良反应的相关性研究

目的:建立超高效液相色谱-串联质谱法(UPLC-MS/MS)测定安罗替尼血药浓度的方法,探讨安罗替尼血药浓度与不良反应的相关性。方法:血浆样品采用乙腈沉淀蛋白进行前处理,以[D5]-氘代安罗替尼为内标;色谱柱:ACQUITY UPLC BEH C₁₈(2.1 mm×50 mm,1.7 μm);流动相:0.01%氨水-甲醇;梯度洗脱,流速0.5 mL·min^-1;柱温40 ℃;进样量0.5 μL;电喷雾离子源,正离子方式,多反应监测模式。对UPLC-MS/MS进行方法学考察,将其用于测定肺癌患者血浆中安罗替尼浓度,收集相关病例的不良反应信息,分析两者之间的相关性。结果:血浆中安罗替尼在5~250 ng·mL^-1内线性关系良好,定量下限为5 ng·mL^-1,标准曲线为y=0.007 2x+0.004 9(r=0.999);批内和批间精密度、提取回收率及稳定性考察均符合要求。共测定了51例患者血浆中安罗替尼的稳态谷浓度,其中8 mg组27例患者的平均质量浓度为(29.08±8.35)ng·mL^-1;12 mg组24例患者的平均质量浓度为(40.79±23.91)ng·mL^-1。发生高血压、蛋白尿、手足综合征或促甲状腺激素升高的患者平均血药浓度均高于未发生相关不良反应患者的平均血药浓度(P＜0.05),相关风险的阈值浓度分别为31.22,23.13,43.15 ng·mL^-1和45.59 ng·mL^-1。结论:该方法准确简便、快速灵敏、重现性好,可用于测定肺癌患者体内安罗替尼的血药浓度。较高的安罗替尼稳态谷浓度会增加患者高血压、蛋白尿、手足综合征和促甲状腺激素升高的发生风险。     

Plasma pharmacokinetics and tissue distribution study of cajaninstilbene acid in rats by liquid chromatography with tandem mass spectrometry

Cajaninstilbene acid (CSA; 3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid) is a major active constituent of pigeonpea leaves, has been proven to be effective in clinical treatment of diabetes, hepatitis, measles and dysentery. A rapid and sensitive liquid chromatography tandem mass spectrometry (LC–MS/MS) method was developed and validated for the determination of CSA in rat plasma and various tissues (brain, heart, lung, liver, spleen, small intestine and kidney) of rat for the first time. Rat plasma and tissue distribution pre-treated by protein precipitation with acetoacetate was analyzed using LC–MS/MS with an electrospray ionization (ESI) interface, and isoliquiritigenin was used as an internal standard. Chromatographic separation was achieved on a HIQ Sil C₁₈ column with the mobile phase of water and methanol (9:91, v/v) containing 0.1% formic acid and resulted in a total run time of 10 min. The isocratic elution mode pumped at a flow rate of 1.0 mL/min. The lower limit of quantification (LLOQ) which was 10 ng/mL. The calibration curve was linear from 10 to 6000 ng/mL (R = 0.9967) for plasma samples and 10 to 6000 ng/mL (R ≥ 0.9974) for tissue homogenates. The intra- and inter-day assay of precision in plasma and tissues ranged from 0.6% to 6.1% and 1.5% to 6.6%, respectively, and the intra- and inter-day assay accuracy was 93.5–104.6% and 93.3–107.5%, respectively. Recoveries in plasma and tissues ranged from 95.0% to 106.8%. The method was successfully applied in pharmacokinetic and tissue distribution studies of CSA after oral administration to rats. The pharmacokinetics of CSA showed rapid absorption and elimination (T_max, 10.7 ± 0.31 min; t_1/2, 51.40 ± 6.54 min). After oral administration in rats, CSA was rapidly and widely distributed in tissues. High concentrations were found in liver and kidney indicating that CSA was possibly absorbed by liver and eliminated by kidney.     

玳玳果黄酮降脂提取物体内组织分布规律及特征研究

目的：建立UPLC-MS/MS分析方法同时测定玳玳果黄酮降脂提取物效应组分新橙皮苷和柚皮苷在大鼠10种脏器组织中含量，分布规律及特征。方法：采用UPLC-MS/MS技术建立提取物效应组分新橙皮苷及柚皮苷在大鼠心、肝、脾、肺、肾、脑、胃、小肠、脂质、肌肉组织中的定量分析方法；大鼠给药后分别于0.33，0.67，1，4，8 h的5个时间点，分别摘取以上10种脏器组织，测定脏器组织及血液中效应组分的质量浓度，采用DAS（V 2.0）药动学软件对各样本的药物浓度-时间数据进行房室拟合，并计算不同组织效应组分的药-时曲线下面积（AUC）及平均滞留时间（MRT）。结果：所建立的UPLC-MS/MS定量分析方法具备良好的专属性、标准曲线及线性范围良好、方法准确度与精密度、定量下限均符合有关规定；玳玳果黄酮降脂提取物效应组分在血液中的分布符合一室模型，除肾脏及脑组织外，其余脏器中提取物效应组分的房室特征多为静脉注射的二室模型，柚皮苷在肾脏中的拟合结果为非静脉注射的二室模型，新橙皮苷在脑组织拟合结果为静脉注射的三室模型，给药后8 h各组织中效应组分新橙皮苷及柚皮苷AUC值大小顺序均为小肠 > 胃 > 肾 > 脂质 ≈ 脾脏 > 肺 > 肌肉 > 肝 > 心 > 脑，效应组分在各脏器中均无明显蓄积；效应组分在血液、肾脏、肝脏中的滞留时间较长，MRT均大于2 h，脂质最短，MRT不足1 h；各脏器中新橙皮苷的药-时曲线下面积约是柚皮苷的3倍，而心、肝、肾中则是3.5，2.1和3.4倍。结论：玳玳果黄酮降脂提取物效应组分在大鼠组织中分布迅速，达峰时间早于血液；效应组分在肠道内消除缓慢，给药8 h后在各脏器中的含量均显著下降且无特异的蓄积部位。研究结果揭示玳玳果黄酮降脂提取物效应组分在大鼠体内的分布特征及规律，为进一步理解玳玳果黄酮降脂提取物在体内的作用靶点及机制奠定了基础。